PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Obtains Patent License from Dnavec for Production of Clinical iPS Cells
October 2, 2014
- Kissei to Spice Up Current Portfolio in Next 3 Years, Launch New Drugs Later
October 1, 2014
- Takeda, MacroGenics Sign Second Agreement to Develop Autoimmune Disease Treatments
October 1, 2014
- Sumitomo Dainippon’s FY2013 Payments to Healthcare Professionals at 13.1 Billion Yen
October 1, 2014
- Kyowa Kirin, Pfizer to Collaborate on Cancer Immunotherapy
October 1, 2014
- Kowa Receives Approval for Glaucoma Treatment Glanatec
October 1, 2014
- AZ Was Concerned with Pfizer’s Possible Takeover Deal Withdrawal Due to US Anti-Inversion Move: CEO
September 30, 2014
- e-Detailing Powerhouse M3 to Establish New Firm Dedicated to CSO Biz
September 30, 2014
- Lixiana OK’d for Stroke Prevention in Japan: Daiichi Sankyo
September 30, 2014
- Daiichi Sankyo to Buy US Biotech Ambit, Beef Up Oncology Portfolio
September 30, 2014
- Kyowa Kirin’s Neutropenia Treatment G-Lasta Approved
September 30, 2014
- JCR Files NDA for Japan’s 1st Cell-Based Drug JR-301
September 30, 2014
- Sumitomo Dainippon, SanBio to Jointly Develop Cell Therapy Agent for Chronic Stroke in North America
September 30, 2014
- Ixekizumab Improves Skin Lesions in Japanese Psoriasis Patients: Eli Lilly Japan
September 30, 2014
- Avigan Administered to Ebola-Infected French Woman: Fujifilm
September 29, 2014
- Sanofi’s 2013 Payments to Healthcare Professionals Down 11%
September 29, 2014
- Novartis Files Panobinostat for Multiple Myeloma in Japan
September 29, 2014
- Sanofi Opens Asia Pacific Development Hub in Shanghai
September 29, 2014
- Ribomic Goes Public, Aims to Swing to Black on Aptamers
September 26, 2014
- NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
September 26, 2014
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…